Navigation Links
Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection
Date:2/12/2009

PHILADELPHIA, Feb. 12 /PRNewswire-USNewswire/ -- When treating children for acute osteomyelitis--a bacterial bone infection--an early changeover from intravenous (IV) antibiotic delivery to oral antibiotics is just as effective as continuing the IV therapy, according to pediatric researchers.

In addition, the oral drugs are more convenient for children and families, and avoid a major drawback of IV use: increased risk of complications from using central catheters, such as infections or breaks in the catheter.

A study team from The Children's Hospital of Philadelphia analyzed hospital records for nearly 2,000 children treated at 29 U.S. pediatric hospitals between 2000 and 2005. Their report appeared in the February issue of Pediatrics. "There had been previous reports with small numbers of patients suggesting that early transition to oral antibiotics was safe and effective," said study leader Theoklis Zaoutis, M.D., M.S.C.E., an infectious diseases specialist at the Center for Pediatric Clinical Effectiveness of Children's Hospital. "This was the first large study of outcomes to directly compare the two practices."

Acute osteomyelitis annually affects at least one in 5,000 children under age 13 in the United States, and results in one percent of all pediatric hospitalizations. Typically caused by the common bacteria Staphylococcus aureus, osteomyelitis usually appears as a fever with some discomfort in a child's leg or arm resulting from the bone infection. The average age of children with the condition is five years.

The traditional treatment has been to supply antibiotics through a central venous catheter over a four- to six-week period after the child returns home from the hospital. Alternatively, children are first treated with IV antibiotics for less than a week, then sent home with oral antibiotics.

In the current study, some 5 percent of the 1,021 children receiving the prolonged IV antibiotic had to return to the hospital for further treatment, compared to 4 percent of the 948 children receiving oral medicine. "The risk of treatment failure was not significantly different between the two groups," said Zaoutis. "But approximately 4 percent of the children receiving the prolonged IV therapy had complications related to the central venous catheter."

Zaoutis's study found wide variability in hospital practices, with some children's hospitals switching over 90 percent of their osteomyelitis patients to oral drugs, and other hospitals using early transition in less than 10 percent of patients. "This study provides evidence that hospitals can orient their clinical guidelines toward early transition to oral medication for acute osteomyelitis in children," added Zaoutis. He cautioned that the study focused on children with uncomplicated infections, and switching to oral therapy may not be appropriate for complicated infections or chronic osteomyelitis.

Zaoutis receives support from the National Institutes of Health, and the Agency for Healthcare Research and Quality provided grant support for this research. Zaoutis's co-authors were Ron Keren, M.D., M.P.H., A. Russell Localio, Ph.D., Kateri Leckerman, M.S., and Stephanie Saddlemire, M.S.P.H., all of Children's Hospital; and David Bertoch, M.H.A., of the Child Health Corporation of America, Shawnee Mission, Kans. Zaoutis, Localio, and Keren also are on the faculty of the University of Pennsylvania School of Medicine.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

    Contact: John Ascenzi
    The Children's Hospital of Philadelphia
    Phone: (267) 426-6055
    Ascenzi@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
3. Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
10. Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Report Details ... Alzheimer,s Disease ... Companies – our new study reveals trends, R&D progress, ... events affecting the Alzheimer,s disease therapeutics and diagnostics market. ... key questions: - How is the Alzheimer,s disease therapeutics ...
(Date:1/19/2017)... Jan. 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ... mitochondrial dysfunction, today announced new additions to its senior ... Chief Medical Officer, and Daniel Geffken as ... Jim Carr , Pharm.D. has been promoted to ... pleased to welcome Doug and Daniel to our management ...
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
Breaking Medicine Technology:
(Date:1/22/2017)... , ... January 22, 2017 , ... Medical lab ... results. Often the results of a simple test will take days to arrive to ... Test Now offers customers direct access to their lab tests, bypassing the cost and ...
(Date:1/21/2017)... ... January 21, 2017 , ... Salveo for life, a ... bringing its product to the United States as part of its presence to expand ... years, Alcovit aims to reduce the productions of nasty toxins as a result of ...
(Date:1/21/2017)... ... January 21, 2017 , ... Seamild, the largest manufacturer of oats in China, ... owner and founder. As Oat is recognized globally as one of the healthiest cereals, ... he believes it is a move to sow the seed of good karma. Buddhism ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica ... Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home 2017,” ... community. “Coming Home 2017” will be held on Friday January 27 through ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
Breaking Medicine News(10 mins):